Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (119,868)	$ (27,692)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,484	1,469
Accretion of premium/discount on marketable securities	(3,495)	0
Non-cash lease expense	250	254
Stock-based compensation expense	70,203	4,036
Change in fair value of stock warrants	0	652
Change in fair value of contingent consideration	2,915	1,633
Other non-cash reconciling items	(3)	(1)
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	279	(177)
Accounts payable	3,094	1,338
Accrued compensation	273	(177)
Accrued clinical trial site costs	(1,631)	15
Operating lease liabilities	(152)	(242)
Other liabilities	1,546	266
Net cash used in operating activities	(45,105)	(18,626)
Cash flows from investing activities
Purchases of property and equipment	(210)	0
Purchases of marketable securities	(308,915)	0
Maturities of marketable securities	77,000	0
Net cash used in investing activities	(232,125)	0
Cash flows from financing activities:
Proceeds from the sale of common stock, net of issuance costs	148,955	0
Proceeds from the sale of common stock and common stock warrants, net of costs	0	17,074
Proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs	5,690	19,445
Proceeds received prior to and for the issuance of common stock and pre-funded warrants	0	19,932
Proceeds from exercise of stock options	1,317	10
Net cash provided by financing activities	155,962	56,461
Net (decrease) increase in cash and cash equivalents	(121,268)	37,835
Cash and cash equivalents, beginning of period	169,681	14,602
Cash and cash equivalents, end of period	48,413	52,437
Supplemental disclosure of non-cash operating and financing information
Operating lease right-of-use assets obtained in exchange for operating lease obligations		597
Unpaid financing costs included in accounts payable and accrued liabilities		$ 199